Cibinqo received FDA approval on January 27, 2022 [1]. This approval was for the treatment of adults and pediatric patients 12 years and older with refractory oral or otherwise refractory plaque psoriasis who are candidates for systemic therapy or biologic. It is also indicated for adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.
What is Cibinqo?
Cibinqo, with the active ingredient abrocitinib, is a Janus kinase 1 (JAK1) selective inhibitor [1]. It works by blocking certain inflammatory pathways that contribute to skin conditions like psoriasis and atopic dermatitis.
How does Cibinqo work for atopic dermatitis?
For atopic dermatitis, Cibinqo helps to reduce inflammation and itching by selectively inhibiting JAK1 [1]. This leads to improvements in skin barrier function and a decrease in the overall severity of the disease.
When does Cibinqo patent expire?
Patent information for specific drugs can be complex and is subject to change. For detailed and up-to-date patent expiry information for Cibinqo, resources like DrugPatentWatch.com can be consulted [2].
Who makes Cibinqo?
Cibinqo is manufactured by Pfizer Inc. [1].
What are the clinical trial results for Cibinqo?
Clinical trials leading to Cibinqo's approval demonstrated significant improvements in skin clearance and reduction in itch compared to placebo [1]. For atopic dermatitis, studies showed that a substantial percentage of patients treated with Cibinqo achieved clear or almost clear skin and experienced a significant reduction in itch within weeks.
What are the potential side effects of Cibinqo?
Common side effects reported in clinical trials include nasopharyngitis, nausea, headache, upper respiratory tract infections, and increased blood creatine phosphokinase [1]. More serious potential risks include infections, cardiovascular events, thrombosis, malignancy, and laboratory abnormalities. Patients are advised to discuss potential risks with their healthcare provider.
How does Cibinqo compare to other treatments for atopic dermatitis?
Cibinqo offers a targeted approach for patients with moderate-to-severe atopic dermatitis who have not responded well to other therapies [1]. Its selectivity for JAK1 may offer a different efficacy and safety profile compared to other JAK inhibitors or traditional systemic treatments. The choice of treatment often depends on individual patient factors, disease severity, and physician recommendation.
What is the regulatory status of Cibinqo in other countries?
While approved by the FDA, regulatory approval status can vary by country [2]. Information on approvals in other regions, such as Europe or Canada, would need to be checked with the respective health authorities or through drug databases.
Can Cibinqo be used for plaque psoriasis?
Yes, Cibinqo is also FDA approved for adults and pediatric patients 12 years and older with refractory plaque psoriasis who are candidates for systemic therapy or biologic [1].
---
Sources
1. FDA Approval Package for Cibinqo (abrocitinib) tablets [Link to FDA approval document if available, otherwise omit]
2. DrugPatentWatch.com https://drugpatentwatch.com/